1 active not recruiting, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Pell Bio-Med Technology Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy Pell's lentiviral-based gene-edited immune cell therapy - Diffuse Large B Cell Lymphoma, Large B-cell Lymphoma | Recruiting | Pell Bio-Med Technology Co., Ltd. | 49 | 2023-03-31 | 2026-10-09 | |
| Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma CD19-targeted chimeric antigen receptor T-cell - Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Pell Bio-Med Technology Co., Ltd. | 49 | 2022-05-31 | 2026-10-09 |
Lymphoma, Large B-Cell, Diffuse (2) · Dendritic Cell Sarcoma, Interdigitating (1)
Taiwan (2)